Fresenius inks deal for 51% stake in Indonesian drugmaker

Eyeing big growth in Indonesia, Germany-based drugmaker Fresenius Kabi has agreed to buy a 51% share in the country's PT Ethica Industri Farmasi. Sources tell The Wall Street Journal that the deal could be worth $200 million. It's just the latest deal in the Asian market, which is expected to grow much faster than Europe and the U.S. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.